Resection of liver metastases remains the only treatment with curative potential for metastatic colorectal cancer to the liver, but unfortunately few patients are eligible for the surgery. For ...
Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, 50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high ...
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis DCC protein expression was assessed immunohistochemically on archival specimens ...
Thermal ablation demonstrated noninferiority to surgical resection for small colorectal liver metastases, with comparable overall survival and local control outcomes. The COLLISION trial showed ...
The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...
Please provide your email address to receive an email when new articles are posted on . Y-90 resin microspheres are the only approved radioembolization therapy for hepatic cellular carcinoma and ...
Adding MRI to CT may improve the accuracy of detecting nonviable disappearing liver metastases than CT alone among patients with initially unresectable colorectal liver metastases. However, confirmed ...
Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, ...
− FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in Japan for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade About FRUZAQLA (fruquintinib) FRUZAQLA is ...
Patients with colorectal cancer (CRC) liver metastases had reduced risk of intrahepatic recurrence when using intraoperative contrast-enhanced ultrasounds. A new study published in Digestive and Liver ...
The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results